Company intelligence / Profile preview

Vicore Health

Ownership: Private
Development stage: Other

Overview

Vicore’s lead asset, buloxibutid (C21), a first-in-class orally available small molecule AT2R agonist, is in phase 2a trials for idiopathic pulmonary fibrosis. The company also develops Almee™, a digital therapeutic with FDA Breakthrough Device Designation to address psychological impacts of pulmonary fibrosis. Additional pipeline programs are in preclinical or early clinical stages targeting severe lung diseases using their ATRAG platform.

Therapeutic areas: PulmonologyPsychiatry
Modalities: Small moleculeDevice
Industry: Biotech

Beyond the preview

Go deeper on Vicore Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vicore Health.

Explore the full profile